NICE Confirms English Funding For Three COVID-19 Drugs, But Rejects Four Others
Executive Summary
There is good news for medicines from Pfizer, GSK and Roche, but MSD, Gilead and AstraZeneca have all appealed against NICE’s decision not to recommend their products for treating COVID-19.
You may also be interested in...
England’s NICE Backs Ultragenx’s Rare Disease Drug Evkeeza After Applying Anti-Discrimination Principles
NICE, the health technology assessment body for England and Wales, looked beyond cost-effectiveness measures alone in its appraisal of Ultragenx’s rare disease drug Evkeeza, resulting in a positive reimbursement recommendation for all eligible patients.
AstraZeneca Proclaims Promising Long-Acting COVID-19 Antibody
AstraZeneca vaccine chief Mark Esser is excited about the first in vitro data on AZD3152 which show that the antibody neutralizes all known variants, from Wuhan to Omicron XBB.1.5.
Cost Recovery Features In UK NICE’s Proposal For Rapidly Updating COVID-19 Treatment Recommendations
The health technology appraisal institute, NICE, is seeking feedback on a new surveillance and rapid update process for COVID-19 treatments.